Please ensure JavaScript is enabled for purposes of website accessibility Diagnosing Thyroid Eye Disease with the SPOT Mnemonic | An HCP Resource

ATTENTION

You are now leaving this educational content and going to a page with information about an FDA-approved treatment for TED.

Okay Cancel

Sign Up

Receive the latest news and updates about Thyroid Eye Disease (TED).

LEARN ABOUT IDENTIFYING THYROID EYE DISEASE (TED)

Spotting TED and treating early can benefit patients and may reduce the impact of the disease, helping avoid potentially permanent eye damage

TED is not a “watch and wait” disease—delaying diagnosis can potentially threaten patients’ vision and impact patients’ quality of life1-4

IGF-1R, insulin-like growth factor-1 receptor; MRI, magnetic resonance imaging; TSHR, thyroid-stimulating hormone receptor; T2, transverse relaxation time.

patient-photo

EARLY DIAGNOSIS AND TREATMENT OF TED IS IMPORTANT AS DAMAGE OFTEN STARTS BEFORE VISIBLE SIGNS APPEAR

thyroideyediseasemnemoniceye

Use the TED mnemonic tool to spot the disease sooner

The TED mnemonic tool below breaks down a differential diagnosis in 4 easy-to-remember steps.

thyroid-eye-disease-mnemonic-s
thyroid-eye-disease-mnemonic-p
  • Proptosis is 1 of the more common signs of TED1
  • Conduct an annual exam to screen for proptosis and other TED signs and symptoms
thyroid-eye-disease-mnemonic-o
thyroid-eye-disease-mnemonic-t
  • TED patients often have a history of autoimmune thyroid conditions, like Graves’ disease3
  • If your patient has a thyroid disorder, screen for TED

Download the Patient Intake Form to help evaluate suspected TED patients or to assess the full impact of TED on their quality of life.

DOWNLOAD
icon-download

If you SPOT 2 or more of these signs or symptoms, download the mnemonic tool and consider TED as part of your differential diagnosis.

DOWNLOAD

Next Page >

Leverage the TED identification tool

  • REFERENCES

    1. Barrio-Barrio J, Sabater AL, Bonet-Farriol E, Velázquez-Villoria Á, Galofré JC. Graves’ ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. J Ophthalmol. 2015;2015:249125.
    2. Bothun ED, Scheurer RA, Harrison AR, Lee MS. Update on Thyroid Eye Disease and management. Clin Ophthalmol. 2009;3:543-551.
    3. Burch HB, Perros P, Bednarczuk T, et al. Management of Thyroid Eye Disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. Thyroid. 2022;32(12):1-32.
    4. Wang Y, Sharma A, Padnick-Silver L, et al. Physician-perceived impact of thyroid eye disease on patient quality of life in the United States. Ophthalmol Ther. 2021;10(1):75-87.
    5. Wang Y, Patel A, Douglas RS. Thyroid Eye Disease: how a novel therapy may change the treatment paradigm. Ther Clin Risk Manag. 2019;15:1305-1318.
    6. Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362(8):726-738.
    7. Thyroid Eye Disease. National Organization for Rare Disorders. 2020. Accessed December 8, 2022. https://rarediseases.org/rare-diseases/thyroid-eye-disease
    8. Cockerham KP, Padnick-Silver L, Stuertz N, Francis-Sedlak L, Holt RJ. Quality of life in patients with chronic Thyroid Eye Disease in the United States. Ophthalmol Ther. 2021;10:975-987.
    9. Data on File. Horizon, April 2020.
    10. Smith TJ, Hegedüs L, Lesser I, Perros P, Dorris K, Kinrade M, Troy-Ott P, Wuerth L, Nori M. How patients experience thyroid eye disease. Front Endocrinol (Lausanne). 2023 Nov 9;14:1283374.